Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10420583 | 0.98 | LMNA (0.50) | LMNACYP3A4L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL13464036 | 0.95 | LMNA (0.52) | LMNACYP3A4L3MBTL1DNM1TSHR | |
| SCHEMBL18893399 | 0.95 | LMNA (0.52) | LMNACYP3A4L3MBTL1DNM1TSHR | |
| SCHEMBL17676328 | 0.95 | LMNA (0.52) | LMNACYP3A4L3MBTL1DNM1TSHR | |
| SCHEMBL15470785 | 0.95 | LMNA (0.52) | LMNACYP3A4L3MBTL1DNM1TSHR | |
| SCHEMBL17199784 | 0.95 | LMNA (0.52) | LMNACYP3A4L3MBTL1DNM1TSHR | |
| SCHEMBL10419386 | 0.95 | LMNA (0.52) | LMNACYP3A4L3MBTL1DNM1TSHR | |
| SCHEMBL13886259 | 0.95 | LMNA (0.52) | LMNACYP3A4L3MBTL1DNM1TSHR | |
| SCHEMBL10419687 | 0.95 | LMNA (0.52) | LMNACYP3A4L3MBTL1DNM1TSHR | |
| SCHEMBL17526633 | 0.93 | LMNA (0.44) | LMNACYP3A4L3MBTL1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | LMNA 3497/4885CYP3A4 1071/4885L3MBTL1 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.